John Gibler is a Global Exchange human rights fellow in Mexico who has been covering social movements since January 1st, 2006. His writing and photographs have appeared in score of independent media.
Gibler's book "Mexico Unconquered: Chronicles of Power and Revolt" takes a look into the history of Mexico and how the country got to where it is today. A country split by a huge financial divide, Mexico is portrayed as a nation of people who don't need much more provocation to be pushed towards rebellion again.
Scott and John discuss governmental corruption, social movements and the powerful drug cartels.
John Gibler is a Global Exchange human rights fellow in Mexico who has been covering social movements since January 1st, 2006. His writing and photographs have appeared in score of independent media.
Gibler's book "Mexico Unconquered: Chronicles of Power and Revolt" takes a look into the history of Mexico and how the country got to where it is today. A country split by a huge financial divide, Mexico is portrayed as a nation of people who don't need much more provocation to be pushed towards rebellion again.
Scott and John discuss governmental corruption, social movements and the powerful drug cartels.
A lawsuit filed by the Nevada attorney general claiming pharmaceutical giants Wyeth, Pfizer and Upjohn misled the public about the safety of their hormone therapy drugs must be heard in state court, not federal court, a federal judge has ruled. Scott discusses the ruling with Zoe Littlepeage. (Littlepage,Booth) in Houston
A lawsuit filed by the Nevada attorney general claiming pharmaceutical giants Wyeth, Pfizer and Upjohn misled the public about the safety of their hormone therapy drugs must be heard in state court, not federal court, a federal judge has ruled. Scott discusses the ruling with Zoe Littlepeage. (Littlepage,Booth) in Houston
Peter Pitts from the Center For Medicine in the Public Interest discusses the Levine v. Wyeth Supreme Court preemption ruling with Scott. Pitts argues it's great for trial lawyers but ultimately bad for consumers and will inhibit drug innovation.
The Obama administration isn’t going to bust stores that are following state laws allowing the sale of marijuana when approved for use by a doctor. But the DOJ will go after stores being used as fronts for drug dealers, Attorney General Eric Holder said yesterday. It’s been clear for a while that the Obama administration would depart from the Bush administration’s practices of using the DEA to bust marijuana dispensaries that officials said were following state law but violating federal law, which doesn’t recognize a medical use of marijuana. Former Deputy District Attorney and prosecutor in Los Angeles, Michael Kraut (Kraut Law Group) discusses the implications with Scott.
Scott Drake talks with David Frederick who represented Diana Levine in the Wyeth Supreme Court case. Frederick talks about how the case was won and the challenges of arguing before the Supreme Court.
David C. Frederick has argued twenty-six cases in the Supreme Court of the United States, including nine in the past three Terms.
Peter Pitts from the Center For Medicine in the Public Interest discusses the Levine v. Wyeth Supreme Court preemption ruling with Scott.
Pitts argues it's great for trial lawyers but ultimately bad for consumers and will inhibit drug innovation.
The Obama administration isn’t going to bust stores that are following state laws allowing the sale of marijuana when approved for use by a doctor. But the DOJ will go after stores being used as fronts for drug dealers, Attorney General Eric Holder said yesterday.
It’s been clear for a while that the Obama administration would depart from the Bush administration’s practices of using the DEA to bust marijuana dispensaries that officials said were following state law but violating federal law,
Scott Drake talks with David Frederick who represented Diana Levine in the Wyeth Supreme Court case. Frederick talks about how the case was won and the challenges of arguing before the Supreme Court.
David C. Frederick has argued twenty-six cases in the Supreme Court of the United States, including nine in the past three Terms.
In a long-awaited legal decision, the U.S. Supreme Court ruled Wednesday that patients who are injured by a drug can sue the drug's manufacturer for damages, even if the drug has been granted FDA approval.
Scott Drake discusses the decision with Brian Wolfman one of Levine's attorneys from Public Citizen, Gerson Smoger President of Public Justice, Leslie Brueckner counsel for Public Justice and Roberta Ashkin, Ashkin Law Firm.
In a long-awaited legal decision, the U.S. Supreme Court ruled Wednesday that patients who are injured by a drug can sue the drug's manufacturer for damages, even if the drug has been granted FDA approval.
Scott Drake discusses the decision with Brian Wolfman one of Levine's attorneys from Public Citizen, Gerson Smoger President of Public Justice, Leslie Brueckner counsel for Public Justice and Roberta Ashkin, Ashkin Law Firm.
In a long-awaited legal decision, the U.S. Supreme Court ruled Wednesday that patients who are injured by a drug can sue the drug's manufacturer for damages, even if the drug has been granted FDA approval.
Scott Drake discusses the decision with Brian Wolfman one of Levine's attorneys from Public Citizen, Gerson Smoger President of Public Justice, Leslie Brueckner counsel for Public Justice and Roberta Ashkin, Ashkin Law Firm.
In a long-awaited legal decision, the U.S. Supreme Court ruled Wednesday that patients who are injured by a drug can sue the drug's manufacturer for damages, even if the drug has been granted FDA approval.
Scott Drake discusses the decision with Brian Wolfman one of Levine's attorneys from Public Citizen, Gerson Smoger President of Public Justice, Leslie Brueckner counsel for Public Justice and Roberta Ashkin, Ashkin Law Firm.
While the Supreme Court Ruled today in Wyeth v. Levine against Wyeth,two lawmakers are working to overturn a year-old Supreme Court decision that took away the rights of consumer to sue when they are injured by defective medical devices. According to The New York Times, Rep. Henry Waxman (D-Calif) and Rep. Frank Pallone (D-New Jersey) plan to soon reintroduce a bill to restore consumers' rights, and similar action is expected in the Senate.
Last February, the Supreme Court ruled in a case called Riegel vs. Medtronic that the Medical Device Amendments of 1976 to the Food, Drug, and Cosmetic Act that require Food & Drug Administration (FDA) approval of medical devices preempt product liability lawsuits in state courts. That law clearly says that states can’t maintain requirements that are different from federal standards. But Congress didn’t specify if those federal standards preempted state common law claims.
Medtronic and the Bush Administration asserted that allowing state personal injury lawsuits against the makers of defective medical devices amounts to a state “requirement” different from FDA requirements because such complaints are based on state laws. Eight members of the high court agreed with Medtronic.
Scott Drake discusses the case with Jan Schlichtmann.